Biologic Therapy & Long-Term Drug
4 articles in this category - 1 cross-referenced - Last updated 2026-05-23
Biologic therapy has reshaped care for rheumatologic, dermatologic, and immunologic disease - but originator biologic pricing in the US and parts of Europe puts these regimens out of reach for many self-pay patients. China's biologic landscape has expanded rapidly, with most originator molecules approved and a growing roster of domestically developed equivalents at materially lower cost.
The articles in this category answer the questions international patients ask most often: Which biologics are accessible in China for rheumatoid arthritis, lupus, psoriasis, severe asthma, and similar conditions? How does cost compare to US and European pricing? What's the workflow for starting a biologic in China and continuing the regimen back home? A fourth article, cross-tagged from Oncology, covers targeted therapy and immunotherapy - where biologic platforms drive modern cancer treatment.
Browse the curated reads below, grouped by the decision they help you make.
Immune-mediated and inflammatory disease
Rheumatology, dermatology, and allergy/immunology are the three specialties where biologic and JAK-inhibitor access most directly reshapes patient outcomes. The three guides below cover Chinese availability of major originator and biosimilar agents, leading centers, realistic pricing, and how to plan a treatment course that bridges Chinese initiation with continued care at home.
Allergy and Immunology in China: Allergen Testing, SCIT/SLIT Immunotherapy, and Severe Asthma
Reading time: 9 minutes Chinese allergy and clinical immunology has grown substantially over the past two decades. Beijing Tongren Hospital established China's first allergy department in 1956, and Peking Union...
Dermatology in China: Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia, and Skin Tumors
Reading time: 9 minutes Dermatology is not a field most patients cross borders for — most common skin conditions are handled at home. But in a narrow set of scenarios,...
Rheumatology in China: RA, Lupus, Ankylosing Spondylitis, and Biologics Access
Reading time: 10 minutes Rheumatologic disease is the prototype of chronic care — rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), Sjögren's syndrome, systemic sclerosis, and others —...
Biologics in cancer treatment
Targeted therapy and immunotherapy - both built largely on biologic platforms - are central to modern cancer care. The article below lives primarily under Oncology but is surfaced here for patients exploring biologic access across all clinical uses, not just inflammatory and immune-mediated disease.
On a biologic regimen and looking at continuing treatment in China - or evaluating switching to a Chinese-approved biosimilar?
Email us your current regimen, condition, country, and travel window. Within 1-2 business days we reply with feasibility, the right hospital route, and a price-range estimate. Free, no commitment.
- MedCareInChina Editorial Team